Articles From: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease to Is identity-theft insurance a waste of money?


2014/3/18
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.
Sign-up for Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease investment picks
2014/1/21
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its fourth quarter 2013 and recent business activities.
Sign-up for Ironwood Pharmaceuticals Provides Fourth Quarter 2013 Investor Update investment picks
2013/10/22
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today provided an update on its third quarter 2013 and recent business activities.
Sign-up for Ironwood Pharmaceuticals Provides Third Quarter 2013 Investor Update investment picks
2014/4/8
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2014 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 29, 2014.
Sign-up for Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter 2013 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, January 21, 2014.
Sign-up for Ironwood Pharmaceuticals to Host Fourth Quarter 2013 Investor Update Call investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will host a live webcast of its Investor Day, which is being held on Thursday, December 12, 2013 beginning at 8:30 a.m. ET in New York City.
Sign-up for Ironwood Pharmaceuticals to Host Investor Day on December 12, 2013 investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2013 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, October 22, 2013.
Sign-up for Ironwood Pharmaceuticals to Host Third Quarter 2013 Investor Update Call investment picks
2014/2/24
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Cowen and Company 34 th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. Eastern Time at The Boston Marriott Copley Place.
Sign-up for Ironwood Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference investment picks
2013/11/6
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Credit Suisse 2013 Healthcare Conference on Tuesday, November 12, 2013 at 3:30 p.m. Mountain Time/5:30 p.m. Eastern Time.
Sign-up for Ironwood Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time at the Westin St.
Sign-up for Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference investment picks
2014/2/7
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 1:50 p.m. Eastern Time at the Waldorf Astoria Hotel in New York.
Sign-up for Ironwood Pharmaceuticals to Present at Leerink Global Healthcare Conference investment picks
2013/9/3
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 4:05 p.m. Eastern Time at the Grand Hyatt New York.
Sign-up for Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference investment picks
2014/2/10
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS® (linaclotide) to treat patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The patent application, co-owned by Ironwood and Forest Laboratories, Inc., is expected to issue in mid-2014 and extend LINZESS patent protection into 2031.
Sign-up for Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS® Patent Protection Through 2031 investment picks
2014/2/5
Expresses Serious Concerns with the Board's Recent, Reactive and Shareholder-Unfriendly Entrenchment Actions States that the Market Currently Reflects the Lack of Confidence in Management's Ability to Unlock Value at MGT Highlights the Substantial Dilution and Loss of Value Shareholders Have Suffered Under CEO Robert Ladd During the Past Three Years Believes Change is Required to Ensure Appropriate Actions are Taken to Improve Execution, Drive Better Financial Performance, Reconstitute the Board and Create Value for All Shareholders NEW YORK , Feb.
Sign-up for Iroquois Capital Delivers Letter to MGT investment picks
2014/1/31
TurboTax ®, the nation’s No.
Sign-up for IRS Accepting E-filed Returns Today investment picks
2014/2/11
BUENOS AIRES, Argentina , Feb.
Sign-up for IRSA Inversiones y Representaciones S.A. Announces Results for the First Six Months 2014 Ended December 31, 2013 investment picks
BUENOS AIRES, Argentina , Sept.
Sign-up for IRSA Inversiones y Representaciones S.A. Announces Results for the Fiscal Year 2013 Ended June, 2013 investment picks
2013/12/12
BUENOS AIRES, Argentina , Dec.
Sign-up for IRSA Inversiones y Representaciones Sociedad Anonima Announces 20-F Filing investment picks
2014/2/12
NEW YORK and ST.
Sign-up for Irving Place Capital Agrees to Sale of Victor Technologies to Colfax Corporation for $947 Million in Cash investment picks
2013/11/20
As foreign inflows continue, frontier-markets funds may grow more volatile and more correlated to U.S. equities.
Sign-up for Is 'Frontier' the New 'Emerging'? investment picks
2008/04/01
First-quarter results challenge conventional thinking.
Sign-up for Is a Key International-Investing Debate Off the Mark? investment picks
2011/01/27
Investors have lost more than $160 billion in structured and complex income investments, says John Wasik.
Sign-up for Is a Structured Product Good for Retirement Income? investment picks
2014/2/20
By Jeff Reeves Amazon.com Inc. has been under pressure in 2014, with the e-commerce giant rolling back about 13% since Jan.
Sign-up for Is Amazon overpriced or underrated? investment picks
2014/4/8
By Russ Britt, MarketWatch Confused investors looking for advice on where biotechnology stocks are headed might get a clue from the head of one company in the sector.
Sign-up for Is biotech caught in a bubble, and is it popping? investment picks
Is Canada Missing the Mark on Innovation and Falling Behind on Entrepreneurship?
Sign-up for Is Canada Missing the Mark on Innovation and Falling Behind on Entrepreneurship? investment picks
2012/08/19
Readers weigh issues of money, accessibility, and proximity to friends and family when deciding whether to move to a smaller home.
Sign-up for Is Downsizing Part of Your Retirement Plan? investment picks
2014/2/20
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Facebook Inc. stunned investors by announcing that it has agreed to buy WhatsApp for $19 billion, a move many analysts quickly portrayed as a defensive -- and expensive -- move.
Sign-up for Is Facebook deal like Google buying YouTube? investment picks
2014/4/2
By Kaitlyn Wells On Thursday, online delivery service GrubHub is expected to debut as a public company, and the timing couldn't be worse.
Sign-up for Is GrubHub going public at the wrong time? investment picks
2014/3/31
By Priya Anand Consumers these days are more worried about fending off hackers than pickpockets.
Sign-up for Is identity-theft insurance a waste of money? investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease to Is identity-theft insurance a waste of money?
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity